# Pharmacovigilance Platform

## Overview

A **Pharmacovigilance Platform** is the drug-safety system of record used by a pharmaceutical company (or a CRO operating safety on its behalf, or a health authority): it collects adverse-event reports about the organization's medicinal products, turns each report into a structured, medically assessed **safety case**, and produces the safety reports that regulators and contractual partners require — expedited case-by-case reports and periodic aggregate reports — while the accumulated case corpus feeds ongoing safety evaluation and signal detection.

The defining structure is small:

```text
Adverse-event safety case (patient × medicinal product × event)
└── Governed case processing → documented medical assessment
    └── Regulatory reporting loop (expedited + periodic, to authorities and partners)
        └── Accumulated case corpus → ongoing safety evaluation
```

Everything else commonly associated with these products — signal-detection statistics, literature screening, AI-assisted intake and coding, partner data exchange networks, multivigilance breadth across devices and cosmetics, regional reporting packs — is standard capability or variant, not what makes the system a pharmacovigilance platform. Remove the safety case, the governed processing, or the reporting loop, and what remains is an adverse-event log, a workflow tool, or a submission utility — not pharmacovigilance.

## Users & Context

Primary users work in a drug-safety (pharmacovigilance) function:

- **Case processors** — receive incoming reports, create and complete case records, run duplicate checks, dispatch follow-up requests, and route cases through the workflow.
- **Medical reviewers (safety physicians)** — perform the medical review of a case: assessed seriousness, expectedness against the product label, and causality between product and event.
- **Coding specialists** — code adverse-event terms and product names against standard medical dictionaries.
- **Regulatory/submission reviewers** — check expedited and periodic reports before they go out.
- **PV operations managers** — watch worklists, workloads, overdue items, and submission compliance across the case population.

Secondary users: quality assurance (audit-readiness of the case record), medical information teams (whose inquiries can originate cases), and affiliate/partner safety staff exchanging cases across a licensing network.

The work context is a regulated one: case records are auditable quality records, processing follows the company's validated procedures, and reporting deadlines are legal obligations. The same platform type also serves **CROs** running safety databases for many sponsor companies, and — in some deployments — **health authorities and national centers**, which process reports received from healthcare professionals and forward them onward to supervisory programmes.

## Core Model

### The safety case

The unit of record is the **adverse-event safety case** (in industry interchange, an ICSR — individual case safety report). One case binds together:

- **Reporter** — who reported (healthcare professional, patient, lawyer, literature author…), with contact and correspondence history.
- **Patient** — demographics, relevant medical history, lab results, special situations (pregnancy, parent/child), death details when applicable.
- **Medicinal product(s)** — the products involved, each with its role in the event (suspect, interacting, concomitant), dosing, dates, and batch/lot information. Product identity is drawn from a controlled product dictionary.
- **Event(s)** — the adverse events, each **coded** against a standard medical terminology so that cases can be aggregated and compared.
- **Product-event assessment** — the medical heart of the case: seriousness (against defined seriousness criteria), expectedness of the event given the product's labeling, and causality between product and event.
- **Narrative** — a written account of the case, revised as new information arrives.
- **Attachments, revisions, and audit trail** — source documents, every follow-up as a new revision, and a complete change history.

A case is not a complaint ticket and not a trial data point: it exists to be medically assessed and, where required, reported. Cases arrive from many channels — spontaneous reports, incoming electronic cases from partners or authorities, literature articles, clinical trials (where serious unexpected trial cases are a distinct, deadline-driven kind), medical-information inquiries, and product-quality complaints that turn out to involve adverse events.

### The processing lifecycle

Each case moves through a governed lifecycle, executed as workflow states with named owners:

```text
Intake / book-in
→ triage & duplicate check
→ data entry (patient, product, event)
→ coding (event terms, product terms)
→ quality review
→ medical review (seriousness / expectedness / causality)
→ follow-up (new information → new case revision)
→ regulatory submission review
→ formal closure
```

Work is organized through worklists (assigned and unassigned cases), action items and queries with due dates, correspondence letters, and routing between states. A case can be locked against further change (with separate local locks per country in some products), copied, or formally closed once its assessments and reporting duties are complete. Every action is attributed and logged.

### The reporting loop

The case corpus exists to discharge reporting obligations:

- **Expedited (per-case) reporting** — for cases that meet regime criteria, the platform schedules a report (manually or automatically, driven by configured reporting rules), generates it in the required format, routes it through approval, and **transmits** it electronically to health authorities and contractual partners. The same machinery handles the **incoming** direction: cases received electronically from partners or authorities are validated, checked for duplicates, and either accepted as new cases or merged as follow-ups.
- **Periodic (aggregate) reporting** — periodic safety reports (known in the industry under names such as PSUR/PBRER, DSUR, or national equivalents) are compiled from the accumulated case corpus: inclusion criteria select the case population, line listings and summary tabulations are generated as of a defined data lock point, the narrative sections are assembled, and the report is scheduled, approved, submitted, and tracked.

Reportability itself is rule-driven: products encode reporting rules (per authority, per product, per case characteristics) that determine which cases must be reported where, and route copies to licensing partners accordingly.

### The accumulated corpus

All completed cases accumulate in the safety database — the organization's memory of its products' safety. The corpus is queried as **case series** (saved filters), analyzed for signals (whether an event-product pairing is appearing more than expected), and summarized in dashboards and compliance reports. In the market this analytics layer is often delivered as companion modules or separate products beside the core case system — which is why it is treated here as a standard capability rather than part of the defining core.

## How It Works

### 1. Intake: from raw report to case

```text
Report arrives (call/email/form/literature/incoming electronic case/trial site)
→ captured into the platform (manually, or via automated intake: email parsing,
  form conversion, AI extraction from documents)
→ duplicate check against existing cases
→ booked in as a new case (or merged as follow-up to an existing one)
→ assigned to a case owner
```

Intake is deliberately multi-channel because reports arrive unstructured. Mature products automate the conversion — extracting patient, product, and event details from emails, PDFs, scanned forms, and literature abstracts — but a case always becomes a structured record before processing continues.

### 2. Process and assess

```text
Complete the case record (patient, products, events, labs, attachments)
→ code event and product terms against standard dictionaries
  (automatic coding first, manual resolution for the remainder)
→ quality review of the data
→ medical review: assess seriousness, expectedness vs. the label,
  and causality for each product-event pair
→ request follow-up from the reporter where information is missing
→ new information arrives → case revision (and, if reportable, a follow-up report)
→ formally close the case when assessments and duties are complete
```

The medical review is the step that makes the record a safety case rather than a data capture: its assessments drive both reportability and the aggregate picture. Reviews are gated — coding review, medical review, and submission review are distinct, attributed steps.

### 3. Report

```text
Reporting rules evaluate the case (authority × product × case characteristics)
→ reportable? → expedited report scheduled (auto or manual)
→ draft generated in the required format
→ reviewed and approved
→ transmitted electronically through a gateway to the authority / partner
→ transmission tracked; failures and overdue reports surfaced

Periodically, per product:
→ select the case population (inclusion criteria, data lock point)
→ generate line listings and summary tabulations
→ assemble and approve the periodic report
→ submit and track it
```

The loop runs in both directions: outgoing submissions are tracked to acknowledgement, and incoming electronic cases (from partners, or retrieved from authority databases) are processed into the same case world.

### 4. Analyze

```text
Query the case corpus (saved filters → case series)
→ run signal detection over product-event combinations
→ review flagged signals medically
→ outcomes feed aggregate reports, labeling discussions, and risk management
```

## Interfaces

The surfaces below are described conceptually; exact layouts and names vary by product.

### Worklist / inbox

The processor's home. Lists assigned and unassigned cases with workflow state, priority, and overdue indicators. Primary actions: open a case, route it, reassign, act on action items.

### Case form

The case record itself, organized in tabs or sections (general/reporter, patient, products, events, assessment, attachments, narrative). Primary actions: enter and edit data, code terms, record assessments, add follow-up information, attach documents, lock, close.

### Coding window

A dictionary browser beside the case: search the medical terminology hierarchy, pick or confirm coded terms, resolve autocode failures. Shows coding status per term.

### Review pages

Dedicated surfaces for medical review, coding review, and submission review — each showing the reviewer the relevant case content and recording the review decision.

### Expedited report queue

Scheduled, draft, approved, and transmitted reports with status, routing details, and overdue flags. Primary actions: schedule, generate, approve, transmit, print, track.

### Incoming case queue

Electronically received cases awaiting validation and duplicate resolution. Primary actions: validate, compare with existing cases (differences view), accept as new case or follow-up, reject.

### Periodic report workspace

Report definitions with inclusion criteria, data lock point, line listings, summary tabulations, templates, schedules, and submission history.

### Case series / filters

Saved queries over the case corpus, shareable between users, exportable — the bridge between case processing and analysis.

### Dashboards

Compliance and operations views: case volumes, workload, aging, overdue submissions, signal indicators.

### Administration / configuration

Product dictionary and reporting-rule configuration, workflow and review-gate setup, dictionary version management, user roles, and gateway connections.

## Important Rules / Behaviors

- **Reportability is rule-driven, not ad hoc.** Configured reporting rules — per authority, product, and case characteristics — determine whether a case must be reported, to whom, and route copies to partners. The same machinery suppresses duplicate reports and handles blinded cases; in some products it can force distribution of a report even while the case remains blinded.
- **Assessed fields are protected.** Once a case has passed certain states, its assessed seriousness and determined expectedness (listedness) can no longer be freely edited — they are the conclusions the reporting chain stands on.
- **Follow-up creates revisions, not overwrites.** New information on a known case produces a new case revision (and, where reportable, a follow-up report); the history of revisions remains inspectable.
- **Duplicates are a first-class concern.** The same event reported by multiple channels is detected at entry and on incoming electronic cases, with a differences view to support the merge-or-new-case decision.
- **Locks protect the record.** Cases can be locked against change — globally, or locally per country — reflecting the different reporting needs of different authorities on the same case.
- **Formal closure is conditional.** A case closes only when its assessments are complete and its reporting duties discharged; open action items and pending follow-ups block closure.
- **Everything is attributable.** The audit trail records who changed what and when; correspondence (including letters with sent and due dates) is tracked on the case.
- **Outputs are anonymization-sensitive.** Case outputs (electronic reports, listings) apply anonymization rules to satisfy privacy requirements in different jurisdictions.
- **Trial cases carry special semantics.** Cases from blinded studies may require unblinding before assessment; serious unexpected trial cases are tracked as their own deadline-driven category.

## Variants

- **By operator:** marketing authorization holder (the classic deployment — one company's global safety database), CRO safety service (many sponsor databases operated by one safety provider), health authority / national center (reports received from the field, forwarded to supervisory programmes).
- **By domain scope:** drug-only platforms vs. **multivigilance** platforms that run pharmacovigilance, medical-device vigilance, cosmetovigilance, nutrivigilance, and biovigilance as configurations of the same system.
- **By deployment:** validated on-premises enterprise installations vs. cloud SaaS (often multitenant, with global worklists across legal entities).
- **By regional regime:** products carry regime packs — country-specific data entry, local locking, and electronic reporting formats for different authorities.
- **By scale:** from small-volume deployments (small annual case counts, priced accordingly in some products) to global databases processing high case volumes across large product portfolios.

## Related Application Types

| Application Type | Distinction |
|---|---|
| Medical Device Post-Market Surveillance | The same loop shape (field events → case processing → reportability → regulator reports → trends) over the **device** object, with device-regime artifacts (device incident reports, device exchange formats). Multivigilance platforms realize both domains as configurations of one system; the drug version is defined by medicinal-product binding and drug-regime reporting. |
| Clinical Trial Management System / Electronic Data Capture | Manage trial conduct and capture adverse events as **trial data**; trial cases flow into the pharmacovigilance platform to be processed as safety cases with reporting duties. The trial systems do not run the reporting loop. |
| Regulatory Information Management (RIM) | The registration/dossier/submission estate. Distinct record world: regulatory documents and submissions vs. safety events and cases; vendors typically sell them as separate suites. |
| Life Sciences QMS / CAPA Management | Quality events (deviations, nonconformances, complaints) and corrective action — a different event class and lifecycle; safety findings may trigger CAPAs, but the case world is separate. |
| Complaint & Escalation Management | Unregulated customer complaints vs. regulated adverse-event cases; a product complaint that reveals an adverse event is promoted into a safety case. |
| Public Health Surveillance Platform | Population-level disease monitoring (aggregates, outbreaks) vs. per-case product safety; different unit of record and different actors. |
| EHR / Health Information Exchange | Patient-care records vs. product-safety case records; the safety case is product- and event-centric, not care-centric. |

The most important boundary is with **Medical Device Post-Market Surveillance**: the two types share their loop shape, and several vendors sell one platform configured for both. The seam is the regulated object and its regime artifacts — medicinal products with drug-safety exchange formats and periodic drug-safety reports versus devices with device-incident reporting. A pharmacovigilance platform whose product records and reporting rules are all drug-regime artifacts remains this type even when it also carries a device tab.

## Representative Products

- **Oracle Argus Safety** (marketed within Safety One Argus) — the long-dominant enterprise platform; case management with companion products for E2B interchange, periodic reporting, analytics, and signal management.
- **ArisGlobal LifeSphere MultiVigilance** — cloud-native, automation-first case processing ("touchless" intake-to-submission), positioned across enterprise and smaller organizations.
- **AB Cube SafetyEasy** — modular multivigilance SaaS (pharmacovigilance, device, cosmetovigilance, nutrivigilance, biovigilance), used by biotechs, CROs, cosmetics and nutraceutical companies, and health authorities; also distributed by EXTEDO.

## Sources

Research date: **2026-09-09**

- Oracle — Argus Safety Documentation (landing page, 8.4.1 Get Started, Books list, Argus Safety User's Guide table of contents): https://docs.oracle.com/en/industries/health-sciences/argus-safety/ , https://docs.oracle.com/en/industries/life-sciences/argus-safety/8.4.1/index.html , https://docs.oracle.com/en/industries/life-sciences/argus-safety/8.4.1/books.html , https://docs.oracle.com/en/industries/life-sciences/argus-safety/8.4.1/aeoaf/toc.htm
- Oracle — Pharmacovigilance solution page: https://www.oracle.com/industries/life-sciences/pharmacovigilance/
- ArisGlobal — LifeSphere MultiVigilance product page: https://www.arisglobal.com/lifesphere/safety/multivigilance-system/
- AB Cube — SafetyEasy Suite and SafetyEasy Vigilance product pages: https://www.ab-cube.com/ , https://www.ab-cube.com/vigilance/
- EXTEDO — Safety Management Hub (SafetyEasy powered by AB Cube): https://www.extedo.com/software/pharmacovigilance-and-drug-safety

> Sourcing limitations: Oracle's documentation was reachable at documentation level (product definition, component structure, and the case/reporting workflow as documented in user-guide structure); ArisGlobal and AB Cube evidence comes from official product pages rather than help centers. Veeva Vault Safety and UMC VigiFlow (a regulator-side product) could not be reached from the research environment; the regulator-side realization is therefore described as a variant with reduced assertion strength, and no precise operational details (numeric deadlines, exact state names, statistical thresholds) are stated in this document.

Detailed product-by-product observations, the cross-product comparison, and the historical market-sample check are recorded in the paired Research Notes.
